eLife (May 2024)
mitoBKCa is functionally expressed in murine and human breast cancer cells and potentially contributes to metabolic reprogramming
- Helmut Bischof,
- Selina Maier,
- Piotr Koprowski,
- Bogusz Kulawiak,
- Sandra Burgstaller,
- Joanna Jasińska,
- Kristian Serafimov,
- Monika Zochowska,
- Dominic Gross,
- Werner Schroth,
- Lucas Matt,
- David Arturo Juarez Lopez,
- Ying Zhang,
- Irina Bonzheim,
- Florian A Büttner,
- Falko Fend,
- Matthias Schwab,
- Andreas L Birkenfeld,
- Roland Malli,
- Michael Lämmerhofer,
- Piotr Bednarczyk,
- Adam Szewczyk,
- Robert Lukowski
Affiliations
- Helmut Bischof
- ORCiD
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany
- Selina Maier
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
- Piotr Koprowski
- Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland
- Bogusz Kulawiak
- ORCiD
- Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland
- Sandra Burgstaller
- ORCiD
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany; NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany; Center for Medical Research, CF Bioimaging, Medical University of Graz, Graz, Austria
- Joanna Jasińska
- Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland
- Kristian Serafimov
- Institute of Pharmaceutical Sciences, Pharmaceutical (Bio-)Analysis, University of Tübingen, Tübingen, Germany
- Monika Zochowska
- Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland
- Dominic Gross
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany
- Werner Schroth
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany
- Lucas Matt
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany
- David Arturo Juarez Lopez
- Medical Clinic IV, University Hospital Tübingen, Tübingen, Germany
- Ying Zhang
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany
- Irina Bonzheim
- ORCiD
- Institute of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany
- Florian A Büttner
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany
- Falko Fend
- Institute of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany
- Matthias Schwab
- Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; iFIT Cluster of Excellence (EXC 2180) “Image-guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany; Department of Clinical Pharmacology, Universityhostpital of Tübingen, Tübingen, Germany; Department of Biochemistry and Pharmacy, University of Tübingen, Tübingen, Germany; German Cancer Consortium (DKTK), German Cancer Research Center, Partner Site Tübingen, Tübingen, Germany
- Andreas L Birkenfeld
- ORCiD
- Medical Clinic IV, University Hospital Tübingen, Tübingen, Germany; Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich at the Eberhard Karls University Tübingen, University of Tübingen, Tübingen, Germany; German Center for Diabetes Research (DZD), Neuherberg, Germany
- Roland Malli
- ORCiD
- Center for Medical Research, CF Bioimaging, Medical University of Graz, Graz, Austria; Gottfried Schatz Research Center, Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria; BioTechMed Graz, Graz, Austria
- Michael Lämmerhofer
- Institute of Pharmaceutical Sciences, Pharmaceutical (Bio-)Analysis, University of Tübingen, Tübingen, Germany
- Piotr Bednarczyk
- ORCiD
- Department of Physics and Biophysics, Warsaw University of Life Sciences (SGGW), Warsaw, Poland
- Adam Szewczyk
- ORCiD
- Laboratory of Intracellular Ion Channels, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland
- Robert Lukowski
- ORCiD
- Department of Pharmacology, Toxicology and Clinical Pharmacy, Institute of Pharmacy, University of Tübingen, Tübingen, Germany
- DOI
- https://doi.org/10.7554/eLife.92511
- Journal volume & issue
-
Vol. 12
Abstract
Alterations in the function of K+ channels such as the voltage- and Ca2+-activated K+ channel of large conductance (BKCa) reportedly promote breast cancer (BC) development and progression. Underlying molecular mechanisms remain, however, elusive. Here, we provide electrophysiological evidence for a BKCa splice variant localized to the inner mitochondrial membrane of murine and human BC cells (mitoBKCa). Through a combination of genetic knockdown and knockout along with a cell permeable BKCa channel blocker, we show that mitoBKCa modulates overall cellular and mitochondrial energy production, and mediates the metabolic rewiring referred to as the ‘Warburg effect’, thereby promoting BC cell proliferation in the presence and absence of oxygen. Additionally, we detect mitoBKCa and BKCa transcripts in low or high abundance, respectively, in clinical BC specimens. Together, our results emphasize, that targeting mitoBKCa could represent a treatment strategy for selected BC patients in future.
Keywords